GlassScriptPhysician profile
Subramanian Krishnan
NPI 1528267358
$1,444.62
in general payments reported to CMS, 2019-2025
19 companies · $75.52 in 2025
The $75.52 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,127 · 2020: $122 · 2021: $71.78 · 2022: $21.70 · 2024: $26.89 · 2025: $75.52.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $102.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $102.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $154.00 | 2019-2025 | Camzyos |
| Novartis Pharmaceuticals Corporation | $152.55 | 2019-2024 | |
| Lundbeck LLC | $142.94 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $139.60 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $120.10 | 2019 | |
| Amarin Pharma, INC. | $113.66 | 2019 | |
| Pfizer INC. | $111.58 | 2019-2025 | |
| Amgen INC. | $108.97 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $76.81 | 2019 | |
| Medtronic, INC. | $71.78 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $48.66 | 2019-2020 | |
| Gilead Sciences, INC. | $39.86 | 2019 | |
| Boston Scientific Corporation | $31.22 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $28.78 | 2019 | |
| Preventice Services, LLC | $23.22 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $22.79 | 2025 | Cardiomems |
| Merck Sharp & Dohme LLC | $21.70 | 2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $19.90 | 2019 | |
| Bardy Diagnostics, INC. | $16.50 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Subramanian Krishnan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.